Osterweis Capital Management Inc. boosted its holdings in Novartis AG (NYSE:NVS) by 2.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 543,208 shares of the company’s stock after buying an additional 10,740 shares during the period. Novartis accounts for approximately 3.2% of Osterweis Capital Management Inc.’s holdings, making the stock its 2nd biggest position. Osterweis Capital Management Inc.’s holdings in Novartis were worth $45,607,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Capital Bank & Trust Co grew its position in shares of Novartis by 5.5% during the third quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock valued at $11,865,000 after purchasing an additional 7,201 shares in the last quarter. Atlantic Trust Group LLC grew its position in Novartis by 54.2% in the third quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after acquiring an additional 25,452 shares in the last quarter. Rothschild Investment Corp IL grew its position in Novartis by 26.9% in the fourth quarter. Rothschild Investment Corp IL now owns 26,200 shares of the company’s stock worth $2,200,000 after acquiring an additional 5,550 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Novartis in the third quarter worth about $1,245,000. Finally, Cedar Hill Associates LLC bought a new stake in Novartis in the third quarter worth about $248,000. Institutional investors and hedge funds own 10.80% of the company’s stock.
Several brokerages have issued reports on NVS. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research note on Thursday, January 18th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Zacks Investment Research downgraded shares of Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Nord/LB reissued a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $87.51.
Shares of Novartis AG (NYSE:NVS) traded down $0.03 on Wednesday, hitting $82.24. 1,580,000 shares of the stock were exchanged, compared to its average volume of 1,820,000. The stock has a market capitalization of $214,570.00, a price-to-earnings ratio of 25.07, a PEG ratio of 1.93 and a beta of 0.78. The company has a quick ratio of 0.91, a current ratio of 1.21 and a debt-to-equity ratio of 0.31. Novartis AG has a 12-month low of $72.67 and a 12-month high of $94.19.
Novartis (NYSE:NVS) last posted its earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.04. The company had revenue of $12.92 billion during the quarter, compared to the consensus estimate of $12.65 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 earnings per share. equities research analysts forecast that Novartis AG will post 5.36 EPS for the current fiscal year.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.